In September 2025, the U.S. stock market is experiencing a notable upswing, with major indices such as the Nasdaq and S&P 500 reaching record highs, driven in part by strong performances from technology stocks. In this dynamic environment, identifying high-growth tech stocks requires careful consideration of factors like innovation potential and market adaptability to leverage current economic trends effectively.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| ACADIA Pharmaceuticals | 10.94% | 26.66% | ★★★★★☆ |
| Palantir Technologies | 25.10% | 31.65% | ★★★★★★ |
| Workday | 11.32% | 31.06% | ★★★★★☆ |
| RenovoRx | 65.52% | 68.63% | ★★★★★☆ |
| OS Therapies | 56.64% | 68.61% | ★★★★★☆ |
| Vanda Pharmaceuticals | 22.66% | 59.11% | ★★★★★☆ |
| Gorilla Technology Group | 32.75% | 122.61% | ★★★★★☆ |
| Circle Internet Group | 28.59% | 82.71% | ★★★★★☆ |
| Aldeyra Therapeutics | 42.88% | 74.81% | ★★★★★☆ |
| Zscaler | 15.74% | 40.36% | ★★★★★☆ |
Click here to see the full list of 67 stocks from our US High Growth Tech and AI Stocks screener.
Here's a peek at a few of the choices from the screener.
Neurocrine Biosciences (NBIX)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Neurocrine Biosciences, Inc. is engaged in the discovery, development, and marketing of pharmaceuticals targeting neurological, neuroendocrine, and neuropsychiatric disorders worldwide with a market cap of $14.16 billion.
Operations: Neurocrine Biosciences focuses on the research, development, and commercialization of pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders. The company generates $2.51 billion in revenue from these activities.
Neurocrine Biosciences, a participant in the dynamic biotech sector, has demonstrated robust financial and operational growth. With an annual revenue increase of 11.2% and earnings growth forecast at 25.9%, the company outpaces both its industry and broader market averages, which stand at 65.2% and 15.4%, respectively for earnings growth comparisons. Recent strategic alliances, like the one with PicnicHealth utilizing AI to enhance patient care in rare diseases, underscore Neurocrine's commitment to innovation in medical treatments. This forward-thinking approach is further evidenced by their active participation in numerous influential conferences aimed at neuropsychiatry advancements, positioning them well for sustained influence within biotech circles.
- Take a closer look at Neurocrine Biosciences' potential here in our health report.
Assess Neurocrine Biosciences' past performance with our detailed historical performance reports.
DoubleVerify Holdings (DV)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: DoubleVerify Holdings, Inc. offers media effectiveness platforms globally and has a market capitalization of approximately $2.12 billion.
Operations: The company generates revenue primarily through its data processing segment, which contributed $714.26 million.
DoubleVerify Holdings, Inc. (DV) is navigating a transformative phase with significant leadership changes and strategic product expansions, positioning itself as an innovative force in digital media measurement. Recently, DV reported a robust 21% increase in sales to $189 million for Q2 2025, underscoring its growth trajectory amidst challenging market conditions. The company's forward-looking approach is evident from its recent launch of enhanced brand suitability tools on social platforms like Meta’s Facebook and Instagram, leveraging AI to refine ad placement accuracy. Furthermore, the discovery of the ShadowBot fraud scheme by DV's Fraud Lab highlights their pivotal role in safeguarding ad integrity, potentially saving millions for advertisers. With these strategic moves and a focus on technological advancement in ad verification and fraud prevention, DV continues to enhance its value proposition in the digital advertising space.
Semrush Holdings (SEMR)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Semrush Holdings, Inc. provides an online visibility management SaaS platform with operations in the United States, the United Kingdom, and internationally, and has a market cap of approximately $1.10 billion.
Operations: The company generates revenue primarily through its software and programming segment, which reported $413.96 million. It operates within the online visibility management sector, offering a SaaS platform to a global market.
Semrush Holdings, amid a competitive tech landscape, is navigating through challenges with a strategic focus on innovation and market adaptation. Despite currently being unprofitable, the company's revenue is expected to grow by 14.5% annually, outpacing the US market average of 9.7%. Semrush's commitment to R&D is underscored by its significant investment in this area, which aligns with its future profitability forecasts and an impressive projected earnings growth of 104.3% per year. Recent initiatives include presenting at high-profile tech conferences and implementing a substantial $150 million share repurchase program, signaling confidence in its financial health and long-term strategy. These efforts are pivotal as Semrush adapts to increasing paid-search costs while still aiming for an ambitious revenue target of up to $446 million for the year.
Where To Now?
- Click this link to deep-dive into the 67 companies within our US High Growth Tech and AI Stocks screener.
- Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
- Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Interested In Other Possibilities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if DoubleVerify Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com